BCAB

BioAtla (BCAB)

About BioAtla (BCAB)

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Details

Daily high

$0.42

Daily low

$0.39

Price at open

$0.40

52 Week High

$2.52

52 Week Low

$0.24

Market cap

22.9M

Dividend yield

0.00%

Volume

27,410

Avg. volume

599,004

P/E ratio

-.32

BioAtla News